Csaba Matyas, Katalin Erdelyi, Eszter Trojnar, Suxian Zhao, Zoltan V Varga, Janos Paloczi, Partha Mukhopadhyay, Balazs T Nemeth, György Haskó, Resat Cinar, Robim M Rodrigues, Yeni Ait Ahmed, Bin Gao, Pal Pacher
BACKGROUND AND AIMS: Hepatic cardiomyopathy, a special type of heart failure, develops in up to 50% of patients with cirrhosis and is a major determinant of survival. However, there is no reliable model of hepatic cardiomyopathy in mice. We aimed to characterize the detailed hemodynamics of mice with bile duct ligation (BDL)-induced liver fibrosis, by monitoring echocardiography and intracardiac pressure-volume relationships and myocardial structural alterations. Treatment of mice with a selective cannabinoid-2 receptor (CB2 -R) agonist, known to attenuate inflammation and fibrosis, was used to explore the impact of liver inflammation and fibrosis on cardiac function...
April 2020: Hepatology: Official Journal of the American Association for the Study of Liver Diseases